文献速递糖尿病肥胖与代谢综合征

急性NEFA调控对2型糖尿病患者及非糖尿病人群肠促胰素诱导胰岛素分泌的影响

Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes.
PubMed 文献 · Diabetologia · 2018-05-07

研究纳入13例2型糖尿病患者和10名非糖尿病志愿者,分别行OGTT和等血糖静脉葡萄糖输注,非糖尿病人群加用外源性脂质输注、糖尿病人群加用阿昔莫司抑制脂解。结果显示升高NEFA可选择性损害非糖尿病人群的肠促胰素效应和胰岛素敏感性,而急性降低NEFA可降低糖尿病患者血糖并改善胰岛素敏感性,但未纠正受损的肠促胰素诱导增强效应。

要点

  • 脂质输注使非糖尿病人群肠促胰素诱导增强效应(PINCR)从1.6[1.1]降至1.3[0.1](p<0.05)。
  • 阿昔莫司使NEFA降低约55%,降低糖尿病患者血糖和总胰岛素分泌并改善胰岛素敏感性。
  • 急性降低NEFA未改变糖尿病患者的β细胞葡萄糖敏感性、PINCR、PGLU及胰高血糖素、GLP-1、GIP反应。

核心结论

  • 在非糖尿病人群中升高NEFA可选择性损害肠促胰素效应和胰岛素敏感性。
  • 在2型糖尿病患者中急性降低NEFA可降低血糖并改善胰岛素敏感性,但未纠正受损的肠促胰素诱导增强效应。

研究设计与样本

  • 研究纳入13例2型糖尿病患者和10名非糖尿病志愿者,先进行3小时OGTT,一周后行等血糖静脉葡萄糖输注(ISO,与OGTT匹配)。
  • 非糖尿病志愿者在脂质输注下重复上述两项检查,2型糖尿病患者在阿昔莫司抑制脂解下重复上述两项检查。
  • 采用胰岛素分泌动力学数学模型评估总胰岛素分泌(TIS)、β细胞葡萄糖敏感性(β-GS)、葡萄糖诱导增强效应(PGLU)和肠促胰素诱导增强效应(PINCR),并以口服葡萄糖敏感性指数估计胰岛素敏感性。

主要发现

  • 脂质输注使OGTT下TIS从61[四分位距26]nmol/m2升至78[31]nmol/m2,ISO下从29[26]nmol/m2升至57[30]nmol/m2,并诱导胰岛素抵抗。
  • 脂质输注使PINCR从1.6[1.1]降至1.3[0.1](p<0.05),β-GS、PGLU及胰高血糖素、GLP-1、GIP反应未受影响。
  • 阿昔莫司使NEFA降低约55%,降低血浆葡萄糖和TIS并增强胰岛素敏感性,但未改变β-GS、PINCR、PGLU及胰高血糖素、GLP-1、GIP反应。
  • 以百分比差异表示,肠促胰素效应在非糖尿病参与者中降低,在糖尿病患者中不变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Incretin effect-the potentiation of glucose-stimulated insulin release induced by the oral vs the i.v. route-is impaired in dysglycaemic states. Despite evidence from human islet studies that NEFA interfere with incretin function, little information is available about the effect in humans. We tested the impact of acute bidirectional NEFA manipulation on the incretin effect in humans. METHODS: Thirteen individuals with type 2 diabetes and ten non-diabetic volunteers had a 3 h OGTT, and, a week later, an i.v. isoglycaemic glucose infusion (ISO; OGTT matched). Both pairs of studies were repeated during an exogenous lipid infusion in the non-diabetic volunteers, and following acipimox administration (to inhibit lipolysis) in people with diabetes. Mathematical modelling of insulin secretion dynamics assessed total insulin secretion (TIS), beta cell glucose sensitivity (β-GS), glucose-induced potentiation (PGLU) and incretin-induced potentiation (PINCR); the oral glucose sensitivity index was used to estimate insulin sensitivity. RESULTS: Lipid infusion increased TIS (from 61 [interquartile range 26] to 78 [31] nmol/m2 on OGTT and from 29 nmol/m2 [26] to 57 nmol/m2 [30] on ISO) and induced insulin resistance. PINCR decreased from 1.6 [1.1] to 1.3 [0.1] (p < 0.05). β-GS, PGLU and glucagon, glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) responses were unaffected. Acipimox (lowering NEFA by ~55%) reduced plasma glucose and TIS and enhanced insulin sensitivity, but did not change β-GS, PINCR, PGLU or glucagon, GLP-1 or GIP responses. As the per cent difference, incretin effect was decreased in non-diabetic participants and unchanged in those with diabetes. CONCLUSIONS/INTERPRETATION: Raising NEFA selectively impairs incretin effect and insulin sensitivity in non-diabetic individuals, while acute NEFA reduction lowers plasma glucose and enhances insulin sensitivity in people with diabetes but does not correct the impaired incretin-induced potentiation.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Astiarraga B, Chueire VB, Souza AL, et al. Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes. Diabetologia. 2018. PMID: 29732475. doi:10.1007/s00125-018-4633-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。